隶属于 government of the united states of america
相关临床试验
90
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1893
进行中（未招募）
1
1.1%
已完成
47
52.2%
尚未招募
1
1.1%
招募中
7
7.8%
终止
8
8.9%
Unknown
21
23.3%
撤回
5
5.6%
暂无批准数据
- The i-STAT Alinity handheld blood testing device can diagnose traumatic brain injuries in just 15 minutes by measuring brain-specific proteins that cross the blood-brain barrier. - The device has received FDA approval, passed clinical trials at Walter Reed Army Institute of Research, and has been deployed to the Middle East for combat use. - Defense funding for TBI research has dropped from $175 million in fiscal 2024 to $40.5 million in fiscal 2026, raising concerns about the future pipeline of diagnostics and treatments. - The new objective blood test replaces subjective cognitive assessments like the Military Acute Concussion Evaluation, which could be manipulated by patients.
- 60 Degrees Pharmaceuticals reported encouraging results from a 6-month commercial pilot that demonstrated increasing demand for ARAKODA among prescribers and overall product sales growth. - The company plans to double its inside sales team, partner with GoodRx for broader patient access, and enhance digital marketing campaigns to accelerate ARAKODA sales in 2026. - Following FDA feedback on its breakthrough therapy designation request for babesiosis, the company will add at least two clinical sites to ongoing babesiosis treatment trials. - The FDA acknowledged that babesiosis meets criteria as a serious or life-threatening condition and suggested resubmitting the breakthrough therapy request with data from ongoing controlled clinical trials.
- Immuron Limited has received a new US Department of Defense subaward to develop two oral therapeutics targeting Campylobacter jejuni and Shigella sonnei using its proprietary hyperimmune bovine colostrum platform technology. - The company expects topline results from its completed Uniformed Services University clinical trial evaluating IMM-124E (Travelan®) for preventing travelers' diarrhea in military personnel to be announced by the end of next week. - The global burden of diarrheal diseases includes an estimated 1.5 billion episodes annually resulting in approximately 2.2 million deaths, with Shigella species causing 80-165 million cases and 600,000 deaths worldwide each year.
- 60 Degrees Pharmaceuticals will submit a Minor Use Minor Species (MUMS) designation request to the FDA for tafenoquine to treat acute canine babesiosis in 2025. - Three independent clinical studies demonstrated that tafenoquine was well tolerated and appeared to facilitate recovery from acute canine babesiosis infection. - Currently no FDA-approved oral treatment exists for canine babesiosis, which affects several hundred to several thousand dogs annually in the United States. - The company's CEO noted that positive canine findings align with earlier research suggesting tafenoquine could be effective against babesiosis in humans.
• Nyrada's lead drug candidate NYR-BI03 demonstrated statistically significant neuroprotection in a preclinical model of penetrating traumatic brain injury, according to a collaborative study with the Walter Reed Army Institute of Research. • The company has commenced recruitment for a Phase 1 clinical trial to assess safety, tolerability, and pharmacokinetics of NYR-BI03, with final readouts expected in Q3 2025. • Previous preclinical studies showed NYR-BI03 rescued 42% of brain tissue in stroke models and provided 86% cardioprotection following myocardial ischemic-reperfusion injury, positioning it as a promising first-in-class treatment.
- Dx&Vx has acquired global development rights from Stanford University for a ferritin-based virus-like particle universal coronavirus vaccine that demonstrated neutralizing antibody levels more than ten times higher than mRNA vaccines in animal studies. - The Phase 1 clinical trials in the United States and South Africa confirmed the vaccine's technological superiority with excellent safety profiles and immune responses compared to mRNA vaccines. - The ferritin platform-based VLP vaccine offers room temperature stability for up to two weeks and can induce both humoral and cellular immune responses, addressing key limitations of current mRNA vaccines. - The company is preparing for global Phase 2 clinical trials with plans to extend administration routes and explore applications against other lethal viruses including influenza and Ebola.
